TY  - JOUR
A1  - Reiners, Christoph
A1  - Schneider, Rita
A1  - Platonova, Tamara
A1  - Fridman, Mikhail
A1  - Malzahn, Uwe
A1  - Mäder, Uwe
A1  - Vrachimis, Alexis
A1  - Bogdanova, Tatiana
A1  - Krajewska, Jolanta
A1  - Elisei, Rossella
A1  - Vaisman, Fernanda
A1  - Mihailovic, Jasna
A1  - Costa, Gracinda
A1  - Drozd, Valentina
T1  - Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey
JF  - Frontiers in Endocrinology
N2  - Published studies on the risk of radiation-induced second primary malignancy (SPM) after radioiodine treatment (RAI) of differentiated thyroid cancer (DTC) refer mainly to patients treated as middle-aged or older adults and are not easily generalizable to those treated at a younger age. Here we review available literature on the risk of breast cancer as an SPM after RAI of DTC with a focus on females undergoing such treatment in childhood, adolescence, or young adulthood. Additionally, we report the results of a preliminary international survey of patient registries from academic tertiary referral centers specializing in pediatric DTC. The survey sought to evaluate the availability of sufficient patient data for a potential international multicenter observational case–control study of females with DTC given RAI at an early age. Our literature review identified a bi-directional association of DTC and breast cancer. The general breast cancer risk in adult DTC survivors is low, ~2%, slightly higher in females than in males, but presumably lower, not higher, in those diagnosed as children or adolescents than in those diagnosed at older ages. RAI presumably does not substantially influence breast cancer risk after DTC. However, data from patients given RAI at young ages are sparse and insufficient to make definitive conclusions regarding age dependence of the risk of breast cancer as a SPM after RAI of DTC. The preliminary analysis of data from 10 thyroid cancer registries worldwide, including altogether 6,449 patients given RAI for DTC and 1,116 controls, i.e., patients not given RAI, did not show a significant increase of breast cancer incidence after RAI. However, the numbers of cases and controls were insufficient to draw statistically reliable conclusions, and the proportion of those receiving RAI at the earliest ages was too low.In conclusion, a potential international multicenter study of female patients undergoing RAI of DTC as children, adolescents, or young adults, with a sufficient sample size, is feasible. However, breast cancer screening of a larger cohort of DTC patients is not unproblematic for ethical reasons, due to the likely, at most slightly, increased risk of breast cancer post-RAI and the expected ~10% false-positivity rate which potentially produced substantial “misdiagnosis.”
KW  - differentiated thyroid carcinoma
KW  - radioiodine therapy
KW  - iodine-131
KW  - long-term complications
KW  - young females
KW  - childhood and adolescence
KW  - second primary malignancy
KW  - breast cancer
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-207766
SN  - 1664-2392
VL  - 11
ER  - 
TY  - THES
A1  - Blasl, Christiana
T1  - Chromatografischer Nachweis endogen radioiodierter Verbindungen im Urin von Patienten mit differenziertem Schilddrüsenkarzinom nach Iod-131-Ganzkörperszintigrafie
T1  - Chromatographic identification of endogenously radioiodinated thyroid products in urine of patients with differentiated thyroid carcinoma after I-131-whole-body-scintigraphy
N2  - Der Follow-UP von Patienten mit differenziertem Schilddrüsenkarzinom (DTC) wird konventionell mit I-131-Ganzkörperzintigrafie (GKS) und Bestimmung des Serumthyreoglobulins (hTg) durchgeführt. Wegen der Inzidenz von 15%-20% diskordanter Resultate entwickelte Bianchi et al. (J Nucl Med 1993; 34: 2032-2037) die Serumchromatografie von endogen radioiodiertem Triiodthyronin (L-T3) und Thyroxin (L-T4) bei Patienten mit DTC nach oraler Applikation von I-131. Da im Rahmen des Iodstoffwechsels auch radioiodierte Verbindungen im Urin erscheinen, versuchten wir eine Urinchromatografiemethode zu entwickeln, basierend auf der Annahme, dass ein pathologischer I-131-Uptake, wenngleich zu niedrig um im GKS erkannt zu werden, gleichwohl über endogen iodierte Schilddrüsenprodukte im Urin nachgewiesen werden kann. In der Urinchromatografie konnten die Ergebnisse der Serumchromatografie nicht erreicht werden.
N2  - Patients with DTC are conventionally followed up with serial I-131- whole-body-scintigraphy (WBS) and serum thyroglobulin (hTg) measurements. Given the 15%-20% incidence of discordant results Bianchi et al. (J Nucl Med 1993; 34: 2032-2037) established the serum chromatographic identification of endogenously radioiodinated thyroid hormones after I-131-WBS in the follow-up of patients with DTC. We tried to establish an urine chromatographic method of patients with DTC, based on the assumption that I-131-uptake, though too low to be detected by I-131-WBS, could be assayed in urine as endogenously labeled and excreted thyroid products. The urine chromatographic method did not show the good results of the serum chromatographic method.
KW  - Differenziertes Schilddrüsenkarzinom
KW  - I-131-Ganzkörperzintigrafie
KW  - Thyreoglobulin (hTg)
KW  - Urinchromatografie
KW  - Serumchromatografie
KW  - differentiated thyroid carcinoma
KW  - I-131-whole-body-scintigraphy
KW  - thyroglobulin (hTg)
KW  - urine chromatographic method
KW  - serum chromatographic method
Y1  - 2004
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-12726
ER  -